Back to Authors

Teuteberg, Jeffrey J

0000-0002-8342-3222

Mayo Clinic

Division of Cardiovascular Medicine, Stanford University School of Medicine, CA (J.J.T.).

Citations 3

Early Serial Assessment of Aggregate Vasoactive Support and Mortality in Cardiogenic Shock: Insights From the Critical Care Cardiology Trials Network Registry
Patel, Siddharth M. , Berg, David D. , Bohula, Erin A. , Baird-Zars, Vivian M., Barsness, Gregory W. , Chaudhry, Sunit‐Preet , Chonde, Meshe , Cooper, Howard A., Ginder, Curtis , Kontos, Michael C. , Miller, P. Elliott , Newby, L. Kristin , O’Brien, Connor , Park, Jeong‐Gun , Pierce, Matthew , Pisani, Barbara , Teuteberg, Jeffrey J. , Katz, Jason N. , Chonde, Meshe D , Miller, P Elliott , Newby, L Kristin , O'Brien, Connor G , Park, Jeong-Gun , Pierce, Matthew J , Pisani, Barbara A , Potter, Brian J , Teuteberg, Jeffrey J , Katz, Jason N , van Diepen, Sean , Morrow, David A , Bohula, Erin A , Berg, David , Patel, Siddharth M , Ginder, Curtis , Jentzer, Jacob C. , Shah, Kevin S , Diepen, Sean van , Morrow, David A.

Circulation: Heart Failure | April 8, 2024 | Volume: 17 | Issue: 5 | Pages: No page available

10.1161/circheartfailure.124.011736 Get It

BACKGROUND: Associations of early changes in vasoactive support with cardiogenic shock (CS) mortality remain incompletely defined. METHODS: The Critical Care Cardiology Trials Network is a multicenter registry of cardiac intensive care units. Patients admitted with CS (2018–2023) had vasoactive dosing assessed at 4 and 24 hours from cardiac intensive care unit admission and quantified by the vasoactive-inotropic score (VIS). Prognostic associations of VIS at both time points, as well as change in VIS from 4 to 24 hours, were examined. Interaction testing was performed based on mechanical circulatory support status. RESULTS: Among 3665 patients, 82% had a change in VIS <10, with 7% and 11% having a ≥10-point increase and decrease from 4 to 24 hours, respectively. The 4 and 24-hour VIS were each associated with cardiac intensive care unit mortality (13%–45% and 11%–73% for VIS <10 to ≥40, respectively; P trend <0.0001 for each). Stratifying by the 4-hour VIS, changes in VIS from 4 to 24 hours had a graded association with mortality, ranging from a 2- to >4-fold difference in mortality comparing those with a ≥10-point increase to ≥10-point decrease in VIS ( P trend <0.0001). The change in VIS alone provided good discrimination of cardiac intensive care unit mortality (C-statistic, 0.72 [95% CI, 0.70–0.75]) and improved discrimination of the 24-hour Sequential Organ Failure Assessment score (0.72 [95% CI, 0.69–0.74] to 0.76 [95% CI, 0.74–0.78]) and the clinician-assessed Society for Cardiovascular Angiography and Interventions shock stage (0.72 [95% CI, 0.70–0.74] to 0.77 [95% CI, 0.75–0.79]). Although present in both groups, the mortality risk associated with VIS was attenuated in patients managed with versus without mechanical circulatory support (odds ratio per 10-point higher 24-hour VIS, 1.36 [95% CI, 1.23–1.49] versus 1.84 [95% CI, 1.69–2.01]; P interaction <0.0001). CONCLUSIONS: Early changes in the magnitude of vasoactive support in CS are associated with a gradient of risk for mortality. These data suggest that early VIS trajectory may improve CS prognostication, with the potential to be leveraged for clinical decision-making and research applications in CS.
Clinician and Algorithmic Application of the 2019 and 2022 Society of Cardiovascular Angiography and Intervention Shock Stages in the Critical Care Cardiology Trials Network Registry
Patel, Siddharth M. , Berg, David D. , Bohula, Erin A. , Baird-Zars, Vivian M., Barnett, Christopher F. , Barsness, Gregory W. , Chaudhry, Sunit‐Preet , Daniels, Lori B. , Diepen, Sean van , Goldfarb, Michael , Katz, Jason N. , Kenigsberg, Benjamin B. , Lawler, Patrick R. , Miller, P. Elliott , Papolos, Alexander , Park, Jeong‐Gun , Prasad, Rajnish, Teuteberg, Jeffrey J. , Investigators, on behalf of the CCCTN, Goldfarb, Michael , van Diepen, Sean , Goldfarb, Michael , Jentzer, Jacob C , Lawler, Patrick , Miller, P Elliott , Potter, Brian J , Singam, N Sarma V , Solomon, Michael A , Teuteberg, Jeffrey J , Morrow, David A , Goldfarb, Michael , Daniels, Lori B , Bohula, Erin A , Berg, David , Patel, Siddharth M , Ghafghazi, Shahab , Jentzer, Jacob C. , Prasad, Rajnish, Singam, Narayana Sarma V. , Sinha, Shashank S , Solomon, Michael A. , Morrow, David A. , Investigators, on behalf of the CCCTN

Circulation: Heart Failure | December 2, 2022 | Volume: 16 | Issue: 1 | Pages: No page available

10.1161/circheartfailure.122.009714 Get It

Background: Algorithmic application of the 2019 Society of Cardiovascular Angiography and Intervention (SCAI) shock stages effectively stratifies mortality risk for patients with cardiogenic shock. However, clinician assessment of SCAI staging may differ. Moreover, the implications of the 2022 SCAI criteria update remain incompletely defined. Methods: The Critical Care Cardiology Trials Network is a multicenter registry of cardiac intensive care units (CICUs). Between 2019 and 2021, participating centers (n=32) contributed at least a 2-month snapshot of consecutive medical CICU admissions. In-hospital mortality was assessed across 3 separate staging methods: clinician assessment, Critical Care Cardiology Trials Network algorithmic application of the 2019 SCAI criteria, and a revision of the Critical Care Cardiology Trials Network application using the 2022 SCAI criteria. Results: Of 9612 admissions, 1340 (13.9%) presented with cardiogenic shock with in-hospital mortality of 35.2%. Both clinician and algorithm-based staging using the 2019 SCAI criteria identified a stepwise gradient of mortality risk (stage C–E: 19.0% to 83.7% and 14.6% to 52.2%, respectively; P trend <0.001 for each). Clinician assignment of SCAI stages identified higher risk patients compared with algorithm-based assignment (stage D: 49.9% versus 29.3%; stage E: 83.7% versus 52.2%). Algorithmic application of the 2022 SCAI criteria, with incorporation of the vasoactive-inotropic score, more closely approximated clinician staging (mortality for stage C-E: 21.9% to 70.5%; P trend <0.001). Conclusions: Both clinician and algorithm-based application of the 2019 SCAI stages identify a stepwise gradient of mortality risk, although clinician-staging may better allocate higher risk patients into advanced SCAI stages. Updated algorithmic staging using the 2022 SCAI criteria and vasoactive-inotropic score further refines risk stratification.